PHARMACEUTICAL COMBINATION OF Atypical Antipsychotic and NMDA Modulator for the Treatment of Schizophrenia, Bipolar Disorder, Cognitive Disorder and Clinical Depression

摘要

This disclosure features combinations of NMDA modulators and atypical antipsychotics. The disclosure provides for example, methods of treating schizophrenia, bipolar disorder, and/or cognitive impairment disorder in a patient in need thereof, comprising administering e.g., rapastinel and an atypical antipsychotic.